Guinn, D., Ruppert, A. S., Maddocks, K., Jaglowski, S., Gordon, A., Lin, T. S., . . . Byrd, J. C. (2014). miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with Ibrutinib. Leukemia.

Guinn, Daphne, et al. "MiR-155 Expression Is Associated With Chemoimmunotherapy Outcome and Is Modulated By Bruton's Tyrosine Kinase Inhibition With Ibrutinib." Leukemia 2014.

Guinn, Daphne, et al. "MiR-155 Expression Is Associated With Chemoimmunotherapy Outcome and Is Modulated By Bruton's Tyrosine Kinase Inhibition With Ibrutinib." Leukemia 2014.